ProQR Therapeutics Stock Forecast, Price & News

ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

Is ProQR Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ProQR Therapeutics stock.
View analyst ratings for ProQR Therapeutics or view top-rated stocks.

How has ProQR Therapeutics' stock price been impacted by COVID-19?

ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PRQR shares have decreased by 10.7% and is now trading at $6.25.
View which stocks have been most impacted by COVID-19.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 833,400 shares, an increase of 23.7% from the December 15th total of 673,600 shares. Based on an average daily volume of 339,400 shares, the days-to-cover ratio is currently 2.5 days. Currently, 1.7% of the company's shares are short sold.
View ProQR Therapeutics' Short Interest.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for ProQR Therapeutics.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.01. The biopharmaceutical company earned $1.03 million during the quarter, compared to analysts' expectations of $0.80 million. ProQR Therapeutics had a negative net margin of 3,747.12% and a negative trailing twelve-month return on equity of 65.00%.
View ProQR Therapeutics' earnings history.

What price target have analysts set for PRQR?

6 brokers have issued 1-year price targets for ProQR Therapeutics' stock. Their forecasts range from $17.00 to $44.00. On average, they anticipate ProQR Therapeutics' share price to reach $26.14 in the next year. This suggests a possible upside of 318.3% from the stock's current price.
View analysts' price targets for ProQR Therapeutics or view top-rated stocks among Wall Street analysts.

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the following people:

• Daniel Anton de Boer, Chief Executive Officer
• Smital Shah, Chief Financial & Business Officer
• Aniz Girach, Chief Medical Officer
• Jennifer Pluim, Vice President-Medical Affairs
• Naveed K. Shams, Chief Scientific Officer

Who are some of ProQR Therapeutics' key competitors?

Some companies that are related to ProQR Therapeutics include FibroGen (FGEN), Amphastar Pharmaceuticals (AMPH), Enanta Pharmaceuticals (ENTA), ImmunoGen (IMGN), Avid Bioservices (CDMO), Madrigal Pharmaceuticals (MDGL), NGM Biopharmaceuticals (NGM), ADC Therapeutics (ADCT), Innoviva (INVA), Keros Therapeutics (KROS), MorphoSys (MOR), Rocket Pharmaceuticals (RCKT), PureTech Health (PRTC), Rani Therapeutics (RANI) and Axsome Therapeutics (AXSM).
View all of PRQR's competitors.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $6.25.

How much money does ProQR Therapeutics make?

ProQR Therapeutics has a market capitalization of $313.78 million and generates $10.80 million in revenue each year. The biopharmaceutical company earns $-53.19 million in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

ProQR Therapeutics employs 1,504 workers across the globe.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is www.proqr.com.

Where are ProQR Therapeutics' headquarters?

ProQR Therapeutics is headquartered at Zernikedreef 9, Leiden P7, 2333 CK.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at [email protected].